2 results
Approved WMOCompleted
The primary objective is to test the hypothesis that galcanezumab is superior to placebo in the prevention of migraine in patients with treatment-resistant migraine.The key secondary objective are:- To compare galcanezumab with placebo with respect…
Approved WMORecruiting
To compare OS between gilteritinib and midostaurin in combination with induction therapy and consolidation therapy followed by one-year maintenance therapy in patients with newly diagnosed AML with a FLT3 gene mutation eligible for intensive…